Union Minister Jagat Prakash Nadda released the 10th edition of the Indian Pharmacopoeia, IP 2026, at Dr Ambedkar International Centre, New Delhi, on January 2, 2026. The Indian Pharmacopoeia is the official compendium of drug standards in India and is legally enforceable under the Drugs and Cosmetics Act, 1940. It is published by the Indian Pharmacopoeia Commission under the Ministry of Health and Family Welfare. The Indian Pharmacopoeia was first published in 1955, so the 2026 edition also marks a long institutional continuity in India’s drug-standard framework.

IP 2026 added 121 new monographs, taking the total number of monographs to 3,340. It includes 20 new monographs for blood transfusion medicine. The coverage also expanded for anti-tubercular, anti-diabetic and anti-cancer drugs, along with iron and micronutrient supplements. For examination purposes, drug standards matter because they relate directly to public health, quality control and legal accountability, making the institution, legal basis and standards list high-yield facts.

For prelims, the high-yield facts are the publishing institution, legal basis, first publication year, edition number and monograph figures. For mains, the same update can be linked with health regulation, drug quality, blood banking quality and the role of public institutions in standard-setting. For RAS and UPSC-style preparation, this is a useful example of current affairs linked with static GK: the Drugs and Cosmetics Act, 1940 provides the legal base, while IP 2026 is the latest standards update. The core facts to retain are the release date, January 2, 2026; the 10th edition; 3,340 total monographs; 121 new monographs; 20 new monographs for blood transfusion medicine; and publication by the Indian Pharmacopoeia Commission.